[
  {
    "title": "3 Value Stocks Walking a Fine Line",
    "published": 1742821347,
    "posting_price": 141.6000061,
    "close_price": 141.74000549,
    "percent_change": 0.09886962
  },
  {
    "title": "Biogen plots new global headquarters in Kendall Square",
    "published": 1742817480,
    "posting_price": 141.6000061,
    "close_price": 141.74000549,
    "percent_change": 0.09886962
  },
  {
    "title": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
    "published": 1742570262,
    "posting_price": 141.24000549,
    "close_price": 140.8999939,
    "percent_change": -0.2407332
  },
  {
    "title": "Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?",
    "published": 1742484626,
    "posting_price": 141.13999939,
    "close_price": 141.38000488,
    "percent_change": 0.17004782
  },
  {
    "title": "Health Canada approves Biogen\u2019s Skyclarys for Friedreich\u2019s ataxia",
    "published": 1742297727,
    "posting_price": 143.16999817,
    "close_price": 143.08999634,
    "percent_change": -0.05587891
  },
  {
    "title": "BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant",
    "published": 1741795920,
    "posting_price": 142.00999451,
    "close_price": 140.19000244,
    "percent_change": -1.28159435
  },
  {
    "title": "Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR",
    "published": 1741780047,
    "posting_price": 142.00999451,
    "close_price": 140.19000244,
    "percent_change": -1.28159435
  },
  {
    "title": "New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer\u2019s approach",
    "published": 1741072317,
    "posting_price": 143.41000366,
    "close_price": 142.6499939,
    "percent_change": -0.52995589
  },
  {
    "title": "QQQ ETF Update, 4/15/2024\ufffd\ufffd\ufffd",
    "published": 1713159000,
    "posting_price": 198.72999573,
    "close_price": 196.80000305,
    "percent_change": -0.97116325
  },
  {
    "title": "Biogen Is Suffering From Doubts About the Future",
    "published": 1712930402,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "GLP-1s benefit Parkinson\u2019s: Barclays sees implications across biopharma",
    "published": 1712919780,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "ClearBridge Aggressive Growth Strategy Q1 2024 Portfolio Manager Commentary",
    "published": 1712906400,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "Biogen price target lowered by $20 at BofA, here's why",
    "published": 1712901420,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map",
    "published": 1712898708,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "SPY ETF Update, 4/12/2024",
    "published": 1712896500,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "Where Biogen Stands With Analysts",
    "published": 1712837160,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "BIIB May 31st Options Begin Trading",
    "published": 1712831760,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "Alkermes' Innovations Are Transforming Mental Health Treatments",
    "published": 1712822460,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "QQQ ETF Update, 4/11/2024",
    "published": 1712816580,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "Biogen price target lowered by $30 at JPMorgan, here's why",
    "published": 1712811720,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)",
    "published": 1712811660,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "ClearBridge Value Equity Strategy Q1 2024 Portfolio Manager Commentary",
    "published": 1712753400,
    "posting_price": 203.0,
    "close_price": 201.55000305,
    "percent_change": -0.71428421
  },
  {
    "title": "SPY ETF Update, 4/10/2024",
    "published": 1712727420,
    "posting_price": 203.0,
    "close_price": 201.55000305,
    "percent_change": -0.71428421
  },
  {
    "title": "10 Health Care Stocks With Whale Alerts In Today's Session",
    "published": 1712666400,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)",
    "published": 1712640660,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "QQQ ETF Update, 4/9/2024",
    "published": 1712639520,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "Biogen Inc. stock outperforms competitors on strong trading day",
    "published": 1712635440,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",
    "published": 1712473500
  },
  {
    "title": "BIIB May 24th Options Begin Trading",
    "published": 1712224920,
    "posting_price": 207.24000549,
    "close_price": 205.30000305,
    "percent_change": -0.93611387
  },
  {
    "title": "SPY ETF Update, 4/4/2024\ufffd\ufffd\ufffd",
    "published": 1712194620,
    "posting_price": 207.24000549,
    "close_price": 205.30000305,
    "percent_change": -0.93611387
  },
  {
    "title": "QQQ ETF Update, 4/3/2024",
    "published": 1712123160,
    "posting_price": 207.71000671,
    "close_price": 206.38000488,
    "percent_change": -0.64031669
  },
  {
    "title": "Biogen price target lowered by $15 at Barclays, here's why",
    "published": 1712119200,
    "posting_price": 207.71000671,
    "close_price": 206.38000488,
    "percent_change": -0.64031669
  },
  {
    "title": "Looking Into Biogen's Recent Short Interest",
    "published": 1712112480,
    "posting_price": 207.71000671,
    "close_price": 206.38000488,
    "percent_change": -0.64031669
  },
  {
    "title": "Biotech Roundtable: Who will bring the next CRISPR drug to market?",
    "published": 1712054340,
    "posting_price": 213.08999634,
    "close_price": 207.63999939,
    "percent_change": -2.55760338
  },
  {
    "title": "Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "published": 1712008219,
    "posting_price": 215.69000244,
    "close_price": 214.83000183,
    "percent_change": -0.39872066
  },
  {
    "title": "Buy Rating on Biogen: Focused on Leqembi\u2019s IV Dosing Amidst SQ Formulation Delay",
    "published": 1711961220,
    "posting_price": 215.69000244,
    "close_price": 214.83000183,
    "percent_change": -0.39872066
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)",
    "published": 1711955460,
    "posting_price": 215.69000244,
    "close_price": 214.83000183,
    "percent_change": -0.39872066
  },
  {
    "title": "QQQ ETF Update, 4/1/2024",
    "published": 1711953660,
    "posting_price": 215.69000244,
    "close_price": 214.83000183,
    "percent_change": -0.39872066
  },
  {
    "title": "Eisai submits sBLA for monthly maintenance dose of Alzheimer's drug Leqembi",
    "published": 1711948020,
    "posting_price": 215.69000244,
    "close_price": 214.83000183,
    "percent_change": -0.39872066
  },
  {
    "title": "Biogen delayed Leqembi submission brings questions, says Barclays",
    "published": 1711946040,
    "posting_price": 215.69000244,
    "close_price": 214.83000183,
    "percent_change": -0.39872066
  },
  {
    "title": "Hold Rating on Biogen Amidst Leqembi\u2019s Regulatory Challenges and Competitive Pressures",
    "published": 1711945620,
    "posting_price": 215.69000244,
    "close_price": 214.83000183,
    "percent_change": -0.39872066
  }
]